|
|
|
|
||
Re: NYT article on Kyle Bass and his "altruism"Unfortunately, Celgene references in article are not positive as they do not include the latest rebuff of a Bass claim, nor state that claim that is moving forward is a meaningless patent expiring in 2018, relative to Revlimid's total patent protection ... polymorph, etc. Not sure if this plays into Monday, but Gretchen M. has a following. |
return to message board, top of board |